| Project/Area Number |
24890170
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
ITO Shingo 熊本大学, 大学院生命科学研究部, 助教 (20466535)
|
|---|
| Project Period (FY) |
2012-08-31 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | オーファントランスポーター / タンパク質翻訳後修飾 / がん治療標的分子 / 腫瘍形成 / 細胞内代謝調節 / O-GlcNAc化修飾 / 定量的標的プロテオミクス / がん治療 |
|---|
| Research Abstract |
We detected the expression of SLC22A18, an orphan transporter and tumor suppressor gene, in organelle membranes, but not within the plasma membrane. We showed that the level of UDP-GlcNAc, an O-GlcNAc modification substrate, is higher in cells stably expressing SLC22A18 than in mock cells. In addition, the levels of O-GlcNAc-modified proteins detected using western blot analysis are increased in cells stably expressing SLC22A18. We found that SLC22A18 knockdown in some tumor cell types increased cell proliferation rates, suggesting that a relationship exists between low SLC22A18 levels and acceleration of tumorigenesis.
|
